Illumina logo

Exploring the Power of Multiomic Solutions Seminar at the CSM Centre for Health Genomics and Informatics

Reveal the power of the 6-base genome – Introducing, duet multiomics solution evoC
7 May 2024
to 7 May 2024
9:00 am
to 12:00 pm
MDT
University of Calgary
, Calgary AB T2N 4N1

About the event

Come learn about new advances in Methylation sequencing, Single Cell and Spatial sequencing. Topics will cover epigenetics, transcriptomes, immune repertoire, metabalomics, and more. Meet Illumina and the CSM Centre for Health Genomics and Informatics teams to discuss how your labs can get started with these assays.
Lunch will be provided.* 

Agenda:

  • 9:00 AM – 9:30 AM | Registration and Coffee
  • 9:30 AM – 10:00 AM | Reveal the power of the 6-base genome – Introducing duet multiomics
    solution evoC
    • Timothy Wilson, Field Application Scientist, biomodal
  • 10:00 AM – 10:30 AM | Exciting Advances in Illumina Technology and Roadmap to the Future
    • Speakers: Ryan Vander Werff, Senior Field Applications Scientist, Illumina and Mena Farag,Sr Manager, Genomics Specialists, Illumina
  • 10:30 – 10:45 | Break
  • 10:45 AM – 11:15 AM | Multi-omics data integration at the CHGI
    • Paul Gordon, PhD, Manager, Bioinformatics, CSM Centre for Health Genomics and
      Informatics
  • 11:15 AM – 12:00 PM | Access the full richness of biological complexity with single cell and spatial
    multiomics
    • Adriana Suarez, PhD, Senior Science and Technology Advisor, 10x Genomics
  • 12:00 PM – 12:00 PM | Lunch

Presenting at the event

Reveal the power of the 6-base genome for transformative insights into current and future states of disease

Timothy Wilson

Field Application Scientist

biomodal

9:00am – 12:00 MDT

During this Lunch & Learn, we will discuss how duet multiomics solution evoC  reveals the power of the 6-base genome in one workflow. The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, C, G, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).

This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA).

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Attending from biomodal

Chad Geringer
Director of Sales and Business Development for North America

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

Cambridge Epigenetix is now biomodal